Sol-Gel Technologies (NASDAQ:SLGL) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Sol-Gel Technologies (NASDAQ:SLGL) issued its quarterly earnings results on Thursday. The company reported ($2.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.09) by ($0.04), Zacks reports. The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.30 million. Sol-Gel Technologies had a negative return on equity of 11.80% and a negative net margin of 14.25%.

Sol-Gel Technologies Stock Performance

Shares of SLGL stock traded down $0.95 during trading hours on Thursday, reaching $35.09. The company had a trading volume of 19,061 shares, compared to its average volume of 22,531. The company has a market capitalization of $97.76 million, a P/E ratio of -28.53 and a beta of 1.35. Sol-Gel Technologies has a twelve month low of $4.02 and a twelve month high of $52.26. The stock’s fifty day simple moving average is $33.95 and its 200 day simple moving average is $19.45.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on SLGL shares. Zacks Research upgraded shares of Sol-Gel Technologies to a “hold” rating in a report on Tuesday, October 28th. HC Wainwright upped their price target on shares of Sol-Gel Technologies from $6.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, October 27th. Wall Street Zen lowered shares of Sol-Gel Technologies from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Sol-Gel Technologies in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $50.00.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.